Gland Pharma has appointed Satnam Singh Loomba as Chief Operating Officer (COO) and Senior Management Personnel of the Company with effect from 01 May 2024.Powered by Capital Market - Live News

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Cetrorelix Acetate for Injection, 0.25 mg/vial, Single-Dose Vial (Product). The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Cetrotide for Injection, 0.25 mg/vial, of EMD Serono, Inc. The Company expects to launch this Product in the near-term through its marketing partner. According to IQVIA, the product had US sales of approximately USD 129 million for the twelve months ending February 2024. Cetrorelix Acetate for Injection is used to prevent premature LH surges in women undergoing controlled ovarian stimulation. It blocks the effects of a natural hormone called gonadotropin-releasing hormone (GnRH), which controls the secretion of another hormone called luteinizing hormone (LH), which induces ovulation during the menstrual cycle. Cetrorelix further expands the company`s fertility product line, underscoring its commitment to developing and manufacturing complex injectables to meet patients` unmet needs.Powered by Capital Market - Live News

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial (Product). The Product is expected to be the first generic approval on the market, and the Company expects to launch this product in the near term through its marketing partner. The Product has US sales of approximately USD 92 million for twelve months ending in February 2024, according to IQVIAPowered by Capital Market - Live News

Gland Pharma has allotted 2,400 equity shares under ESOS on 25 March 2024. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs. 164,710,523 /- comprising of 164,710,523 Equity shares of face value Re.1/- each. Powered by Capital Market - Live News

Net profit of Gland Pharma declined 17.28% to Rs 191.86 crore in the quarter ended December 2023 as against Rs 231.95 crore during the previous quarter ended December 2022. Sales rose 64.68% to Rs 1545.16 crore in the quarter ended December 2023 as against Rs 938.29 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales1545.16938.29 65 OPM %23.0630.86 - PBDT388.50348.46 11 PBT283.16310.85 -9 NP191.86231.95 -17 Powered by Capital Market - Live News